

# Integration of Local Therapy with Systemic Treatment in Oligometastatic Disease

ESMO-ESTRO-ESSO Joint Symposium  
Introduction

Christoph C. Zielinski  
Comprehensive Cancer Center  
Medical Univ. Vienna – General Hospital  
Vienna, Austria

# Disclosure slide

- I have no COI to declare

# Clinical Presentation of Malignant Disorders



S. Hellman & R. Weichselbaum, J. Clin. Oncol. 1995



S. Hellman, J. Clin. Oncol. 1994

# **Definition of Oligometastatic Disease**

**1-3 or 1-5 Metastases**

**Synchronous**  
**Metachronous**


# Concept: Long-Term Survival after Ablation of Oligometastatic Disease



# The Oligometastatic Disease Paradigm

**„Patients with Malignancy and a Small Number of Metastases if Treated Aggressively by Local Interventions (Surgery, Stereotaxy, etc) Might Achieve Long-Term Survival.“**

# Overall Survival from First Pulmonary Metastasectomy in Soft Tissue Sarcoma. \*



- S. Schur et al., Eur J Cancer 2014 Jul 2. pii: S0959-8049(14)00659-5. doi: 10.1016/j.ejca.2014.05.009

# Treatment of Oligometastatic Disease

Few Randomized Trials\*

Numerous Non-Randomized Trials and Clinical Observations on Various Patient Sizes with Various Diagnoses\*\*

\* T. Aberg et al., J Thorac Surg 1980; R. Patchell et al., N. Engl. J. Med. 1990; P. McCormack et al., Arch Surg 1992; S. Okumura, J Thorac Cardiovasc Surg 1996; D. Andrews et al., Lancet 2004; T. Ruers et al., Ann Oncol 2012

\*\* J. Barney et al., J. Urol 1939; J.A. van Dongen et al., Cancer Treat. Rev. 1978; J. Wagner et al., Ann. Surg. 1984; B. Nordlinger et al., Cancer 1996; S. Hellman & R. Weichselbaum, J. Clin. Oncol. 1995; M. Selzner et al., Surgery 2000; T. Tanvetyanon et al., J Clin Oncol 2008; E. Morris et al., Br. J Surg. 2010; H. Pan et al., Cancer 2011; P. Gray et al., Lung Cancer 2014; S. Schur et al., Eur. J. Cancer 2014

# Lots of Questions in Oligometastatic Disease

- Longitudinal Concepts Including Systemic and Local Therapies (Delay of Systemic Therapy, Abscopal Effect)
- (Supreme or Different?) Efficacy of Local Therapies incl. Surgery, Radiotherapy and Radiofrequency Ablation
- Predictive Factors (micro-RNAs?)
- Divergent Molecular Characteristics?

## Randomized Trials:

RTOG 0937 (NSCLC) Trial: PCI +/- Radiotherapy

NSCLC Randomized Phase II Trial: Chemotherapy +/- Local Intervention

PulMiCC Trial: Pulmonary Metastasectomy in mCRC

SABR-COMET Trial: Chemo-/Radiotherapy +/- Stereotactic Ablative Radiotherapy

PRIMULA Study (PI: PierFranco Conte, Padova)